In this video, Arshad M. Khanani, MD, MA, FASRS, discusses the results of the phase 2 ARCHER trial of ANX007 from Annexon Biosciences in patients with geographic atrophy, presented at the American Academy of Ophthalmology meeting.
In the trial, patients who received the novel neuroprotective agent monthly or every other month were compared with patients who received sham, according to Khanani, director of clinical research at Sierra Eye Associates.
“The primary endpoint was mean change in GA growth, and ANX007 did not achieve that in terms of reducing the lesion area, but what was